RECURRENT NEUROBLASTOMA

This study tested whether adding an immunotherapy drug (dinutuximab) to standard treatment helps children with high-risk neuroblastoma live longer without the cancer coming back. About 1,400 children who had already received intensive chemotherapy and a stem cell transplant took …

This early-stage trial tested a combination of two lab-made antibodies, magrolimab and dinutuximab, in 12 children and young adults whose neuroblastoma or osteosarcoma had come back or stopped responding to treatment. The main goals were to find the safest dose and see if the dru…

This study tested a drug called samotolisib in 18 children and teens whose cancers had spread, come back, or stopped responding to treatment. The drug works by blocking certain enzymes that cancer cells need to grow. The goal was to see if the drug could shrink or stop the cancer…

This study tested the drug palbociclib in 23 children and young adults (ages 1-21) whose cancers had come back or stopped responding to treatment. The drug works by blocking certain proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the di…

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2 or SWI/SNF) in their tumors. The goal was to see if the drug could shrink or control the cancer. This is a dise…